Accounting for future costs in medical cost-effectiveness analysis

Journal of Health Economics

Volumn 16, Issue 1, 1997, Pages 33-64

  Meltzer, David ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cost benefit analysis; Cost effectiveness analysis; Health care costs; Utility maximization; Welfare economics

Indexed keywords

ACCOUNTING; ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FUTUROLOGY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH MAINTENANCE ORGANIZATION; LIFE EXPECTANCY; QUALITY OF LIFE;

COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HEALTH CARE RATIONING; HEALTH POLICY; HEALTH SERVICES RESEARCH; MODELS, THEORETICAL; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES;

EID: 0030915977     PISSN: 01676296     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-6296(96)00507-3     Document Type: Article

References (44)

1. Avorn, J., 1984, Benefit and cost analysis in geriatric care: Turning age discrimination into health policy, New England Journal Medicine 310, 1294-1301.
2. Bureau of the Census, 1993, Money income of households, families, and persons in the United States: 1992, current population reports, consumer income, series P60-184 (US Department of Commerce, Washington, DC).
3. Bureau of Labor Statistics, 1993, Consumer Expenditure Survey, 1990-1991, Bulletin 2425 (US Department of Labor Statistics, Washington, DC).
4. Bureau of Labor Statistics, 1994, Monthly Labor Review, reported in: Statistical Abstract of the United States (US Bureau of the Census, Washington, DC) .
5. Bush, J.W., M.M. Chen and D.L. Patrick, 1973, Health status index in cost effectiveness: Analysis of PKU program, in: R.L. Berger, ed., Health status indexes (Hospital Research and Educational Trust, Chicago).
6. Desch, C., B. Hillner, T. Smith and S. Retchin, 1993, Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes, Journal of Clinical Oncology 11, 777-782.
7. Eddy, D., 1989, Screening for breast cancer, Annals of Internal Medicine 111, 389-399.
8. Eddy, D., 1990, Screening for cervical cancer, Annals of Internal Medicine 113, 214-226.
9. Fleming, C., J. Wasson, P. Albertson, M. Barry and J. Wennberg, 1993, A decision analysis of alternative treatment strategies for clinically localized prostate cancer, Journal of the American Medical Association 269, 2650-2658.
10. Frame, P.S., D.G. Fryback and C. Patterson, 1993, Screening for abdominal aortic aneurism in men ages 60 to 80 years: A cost-effectiveness analysis, Annals of Internal Medicine 119, 411-416.
11. Fryback D., E. Dosbach, R. Klein, B. Klein, N. Dorn, K. Peterson and P. Martin, 1993, The Beaver Dam health outcomes study: Initial catalog of health-state quality factors, Medical Decision Making, 13(2), 89-102.
12. Garber, A. and C. Phelps, 1992, Economic foundations of cost-effectiveness analysis, working paper 4164 (National Bureau of Economic Research, Cambridge, MA).
13. Garner, T. and R. Dardis, 1987, Cost-effectiveness analysis of end-stage renal disease treatments, Medical Care 25, 25-34.
14. Goldman, L., D. Gordon, B. Rifkind, S. Hulley, A. Detsky, D. Goodman, B. Kinosian and M. Weinstein, 1992. Cost and health implications of cholesterol lowering, Circulation 85, 1960-1968.
15. Goldman, L., M.C. Weinstein, P.A. Goldman and L.W. Williams, 1991, Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease, Journal of American Medical Association 265, 1145-1151.
16. Grossman, M., 1972, On the concept of health capital and the demand for health, Journal of Political Economy 80(2), 223-255.
17. Hansen, G., 1985, Indivisible labor and the business cycle, Journal of Monetary Economics 6(3), 309-327.
18. Hillner, B. and T. Smith, 1991, Efficacy and cost-effectiveness of adjuvant chemotherapy in women with node-negative breast cancer, New England Journal of Medicine 324, 160-168.
19. Homberger, J., D. Redelmeier and J. Petersen, 1992, Variability among methods to assess patients' well-being and consequent effect on a cost-effectiveness analysis, Journal of Clinical Epidemiology 45, 505-512.
20. Johannesson, M., D. Meltzer and R. O'Conor, 1996, Incorporating future costs in medical cost-effectiveness analysis: Implications for the cost-effectiveness of the treatment of hypertension, unpublished manuscript.
21. La Puma, J. and E.F. Lawlor, 1990, Quality-adjusted life-years: Ethical implications for physicians and policymakers, Journal of the American Medical Association 263, 2917-2921.
22. Loomes, G. and L. McKenzie, 1989, The use of QALYs in health care decision making, Social Sciences Medicine 28, 299-308.
23. Mushlin, A.I. and L. Fintor, 1992, Is screening for breast cancer cost-effective? Cancer 69 (Suppl.), 1957-1962.
24. Newhouse, J.P., 1992, Medical care costs: How much welfare loss? Journal of Economic Perspectives 6, 3-21.
25. Nord, E., 1992. Methods for quality adjustment of life years. Social Science and Medicine 34(5), 559-569.
26. Office of Technology Assessment, 1981, Cost-effectiveness of influenza vaccination (Office of Technology Assessment, US Congress, Washington, DC).
27. Prescott, E. and R. Townsend, 1984, General competitive analysis in an economy with private information, International Economic Review 25(1), 1-20.
28. Rosen, S., 1988, The value of changes in life expectancy, Journal of Risk and Uncertainty 1, 285-304.
29. Russell, L.B., 1986, Is prevention better than cure? (The Brookings Institution, Washington, DC).
30. Sculpher, M.J., P. Seed, R. Henderson, M. Buxton, M. Pocock, J. Parker, E. Sowton and J. Hampton, 1994, Health service costs of coronary angioplasty and coronary artery bypass surgery: The randomised intervention treatment of angina (RITA) trial, Lancet 344, 927-930.
31. Smith, R., J. Hall, G. Howard and P. Harnett, 1993, A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Duke's c colonie carcinoma, Medical Journal of Australia 158, 319-322.
32. Sox, H.C., B. Littenberg and A. Gerber, 1989, The role of exercise testing in screening for coronary artery disease. Annals of Internal Medicine 110, 456-469.
33. Stason, W.B. and M. Weinstein, 1977, Allocation of resources to manage hypertension, New England Journal of Medicine 296, 732-739.
34. Torrance, G., 1986, Measurement of health state utilities for economic appraisal, Journal of Health Economics 5, 1-30.
35. Torrance, G. and D. Feeny, 1989, Utilities and quality-adjusted life years, International Journal of Technology Assessment in Health Care 5, 559-575.
36. Tosteson, A. and M. Weinstein, 1991, Cost-effectiveness of hormone replacement therapy after the menopause, Ballière's Clinical Obstetrics and Gynaecology 5, 943-959.
37. Townsend, R., 1986, Arrow-Debreu programs as microfoundations for macroeconomics, NORC Discussion Paper Series, 86-87 (University of Chicago, Chicago).
38. Wagstaff, A., 1991, QALYs and the equity-efficiency trade-off, Journal of Health Economics 10, 21-41.
39. Waldo, D.R., S. Sonnefeld, D. McKusick and R. Arnett, 1989, Health expenditures by age group, 1977 and 1987, Health Care Financing Review 114.
40. Weinstein, M., H. Fineberg, A. Elstein, H. Frazier, D. Newhauser, R. Neutra and B. McNeil, 1980, Clinical decision analysis (Saunders, Philadelphia).
41. Weinstein, M., 1986, Challenges for cost-effectiveness research, Medical Decision Making 6, 194-198.
42. Weinstein, M., P. Coxson, L. Williams, T. Pass, W. Stason and L. Goldman, 1987, Forecasting coronary heart disease incidence, mortality and cost: The coronary heart disease policy model, American Journal of Public Health 77, 1417-1426.
43. Willems, J.S., C. Sanders, M. Riddiough and J. Bell, 1980, Cost effectiveness of vaccination against pneumococcal pneumonia, New England Journal of Medicine 303, 553-559.
44. Wong, J., F. Sonnenberg, D. Salem and S. Pauker, 1990, Myocardial revascularization for chronic stable angina, Annals of Internal Medicine 113, 852-871.